Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 6/2017

03.10.2017 | Strahlenschutz | zertifizierte fortbildung

Brusterhaltendes Vorgehen in der Mammakarzinomtherapie

Personalisierte adjuvante Strahlentherapie beim nodal-negativen Brustkrebs

verfasst von: Anna-Lena Hottinger, Alexandros Papachristofilou, Prof. Dr. Frank Zimmermann

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Wann lässt sich auf eine adjuvante Radiotherapie verzichten, wann reicht eine Bestrahlung des Tumorbetts? In welchen Situationen ist eine hypofraktionierte Radiatio von Vorteil, wann eine Dosiseskalation? In der personalisierten Strahlentherapie des Mammakarzinoms müssen Behandler zahlreiche Aspekte berücksichtigen und Nutzen und Risiken sorgfältig abwägen. Ein Überblick.
Literatur
1.
Zurück zum Zitat Senkus E et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.CrossRefPubMed Senkus E et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.CrossRefPubMed
2.
Zurück zum Zitat Shah C et al. Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. Ann Surg Oncol. 2016;23(12):3880–90.CrossRefPubMed Shah C et al. Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. Ann Surg Oncol. 2016;23(12):3880–90.CrossRefPubMed
3.
Zurück zum Zitat Fortin A et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17(1):101–9.CrossRefPubMed Fortin A et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17(1):101–9.CrossRefPubMed
4.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef
5.
Zurück zum Zitat Morigi C et al. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience. 2017;11:732.CrossRefPubMedPubMedCentral Morigi C et al. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience. 2017;11:732.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Shah C et al. Accelerated partial breast irradiation utilizing brachytherapy: patient selection and workflow. J Contemp Brachytherapy. 2016;8(1):90–4.CrossRefPubMedPubMedCentral Shah C et al. Accelerated partial breast irradiation utilizing brachytherapy: patient selection and workflow. J Contemp Brachytherapy. 2016;8(1):90–4.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chesney TR et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis. Radiother Oncol. 2017;123(1):1–9.CrossRefPubMed Chesney TR et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis. Radiother Oncol. 2017;123(1):1–9.CrossRefPubMed
8.
Zurück zum Zitat Kunkler IH et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.CrossRefPubMed Kunkler IH et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.CrossRefPubMed
9.
Zurück zum Zitat Winzer KJ et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2010;46(1):95–101.CrossRefPubMed Winzer KJ et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2010;46(1):95–101.CrossRefPubMed
10.
Zurück zum Zitat Fyles AW et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70.CrossRefPubMed Fyles AW et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70.CrossRefPubMed
11.
Zurück zum Zitat Tinterri C et al. Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. Breast. 2009;18(6):373–7.CrossRefPubMed Tinterri C et al. Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. Breast. 2009;18(6):373–7.CrossRefPubMed
12.
Zurück zum Zitat Murphy CT et al. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery. Clin Breast Cancer. 2015;15(5):381–9.CrossRefPubMed Murphy CT et al. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery. Clin Breast Cancer. 2015;15(5):381–9.CrossRefPubMed
13.
Zurück zum Zitat Hepel JT et al. American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. Brachytherapy. 2017;16(5):919–28.CrossRefPubMed Hepel JT et al. American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. Brachytherapy. 2017;16(5):919–28.CrossRefPubMed
15.
Zurück zum Zitat Manyam BV et al. Evaluating Candidacy for Hypofractionated Radiation Therapy, Accelerated Partial Breast Irradiation, and Endocrine Therapy After Breast Conserving Surgery: A Surveillance Epidemiology and End Results (SEER) Analysis. Am J Clin Oncol. 2016; https://doi.org/10.1097/COC.0000000000000332. Manyam BV et al. Evaluating Candidacy for Hypofractionated Radiation Therapy, Accelerated Partial Breast Irradiation, and Endocrine Therapy After Breast Conserving Surgery: A Surveillance Epidemiology and End Results (SEER) Analysis. Am J Clin Oncol. 2016; https://​doi.​org/​10.​1097/​COC.​0000000000000332​.​
16.
Zurück zum Zitat Shah C et al. Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. Ann Surg Oncol. 2016;23(12):3880–90.CrossRefPubMed Shah C et al. Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. Ann Surg Oncol. 2016;23(12):3880–90.CrossRefPubMed
17.
Zurück zum Zitat Correa C et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017;7(2):73–9.CrossRefPubMed Correa C et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017;7(2):73–9.CrossRefPubMed
18.
Zurück zum Zitat Owen JR et al. Lancet Oncol. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. 2006;7(6):467–71.CrossRefPubMed Owen JR et al. Lancet Oncol. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. 2006;7(6):467–71.CrossRefPubMed
19.
Zurück zum Zitat Whelan TJ et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefPubMed Whelan TJ et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefPubMed
20.
Zurück zum Zitat START Trialists’ Group et al. Lancet Oncol. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. 2008;9(4):331–41.CrossRef START Trialists’ Group et al. Lancet Oncol. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. 2008;9(4):331–41.CrossRef
21.
Zurück zum Zitat Haviland JS et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed Haviland JS et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed
22.
Zurück zum Zitat START Trialists’ Group et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.CrossRef START Trialists’ Group et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.CrossRef
23.
Zurück zum Zitat Shaitelman SF et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015;1(7):931–41.CrossRefPubMedPubMedCentral Shaitelman SF et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015;1(7):931–41.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Hickey BE et al. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016;7:CD007077.PubMed Hickey BE et al. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016;7:CD007077.PubMed
25.
Zurück zum Zitat Swanick CW et al. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Cancer. 2016;122(18):2886–94.CrossRefPubMedPubMedCentral Swanick CW et al. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Cancer. 2016;122(18):2886–94.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Shaitelman SF et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015;1(7):931–41.CrossRefPubMedPubMedCentral Shaitelman SF et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015;1(7):931–41.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Lalani N et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2014;90(5):1017–24.CrossRefPubMed Lalani N et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2014;90(5):1017–24.CrossRefPubMed
28.
Zurück zum Zitat Litière S et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13(4):412–9.CrossRefPubMed Litière S et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13(4):412–9.CrossRefPubMed
29.
Zurück zum Zitat van Maaren MC et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed van Maaren MC et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed
30.
Zurück zum Zitat Bartelink H et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefPubMed Bartelink H et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefPubMed
31.
Zurück zum Zitat Vrieling C et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial. JAMA Oncol. 2017;3(1):42–8.CrossRefPubMed Vrieling C et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial. JAMA Oncol. 2017;3(1):42–8.CrossRefPubMed
32.
Zurück zum Zitat Poortmans P et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‚boost versus no boost‘ randomised trial. Radiother Oncol. 2004;72(1):25–33.CrossRefPubMed Poortmans P et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‚boost versus no boost‘ randomised trial. Radiother Oncol. 2004;72(1):25–33.CrossRefPubMed
Metadaten
Titel
Brusterhaltendes Vorgehen in der Mammakarzinomtherapie
Personalisierte adjuvante Strahlentherapie beim nodal-negativen Brustkrebs
verfasst von
Anna-Lena Hottinger
Alexandros Papachristofilou
Prof. Dr. Frank Zimmermann
Publikationsdatum
03.10.2017
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 6/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-017-5563-5

Weitere Artikel der Ausgabe 6/2017

InFo Hämatologie + Onkologie 6/2017 Zur Ausgabe